Cell and Gene Therapy Biomanufacturing Market is predicted to reach USD 31.2 billion at a CAGR of 10.60% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Cell and Gene Therapy Biomanufacturing Market”.

The Cell and Gene Therapy Biomanufacturing market is estimated to register a CAGR of 10.60% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Cell and Gene Therapy Biomanufacturing market— Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep and Others.

Cell Gene Therapy Biomanufacturing Market Highlights

The global Cell and Gene Therapy Biomanufacturing market is accounted for to register a CAGR of 10.60% during the forecast period and is estimated to reach USD 31.2 billion by 2032.

The Cell and Gene Therapy Biomanufacturing market is experiencing rapid growth due to several factors. Firstly, advancements in biotechnology have enabled the development of more sophisticated therapies, driving demand. Additionally, increased investment from both private and public sectors has fueled research and development efforts. Furthermore, regulatory agencies have streamlined approval processes, facilitating quicker market entry for innovative therapies. These factors, combined with growing awareness and acceptance of cell and gene therapies, are driving the expansion of the biomanufacturing market.

Segment Analysis

The global Cell and Gene Therapy Biomhanufacturing market has been segmented based on Product Type, Usage, Application, and End User.

On the basis of product Type, the market is segmented into Consumables, Equipment, and Software Solutions. The Consumables dominated the Cell and Gene Therapy Biomanufacturing Market in 2023 due to their essential role in the production process. Consumables such as reagents, media, and culture supplements are indispensable for cell and gene therapy manufacturing. Moreover, the increasing adoption of single-use systems and disposables in biomanufacturing facilities has contributed to the significant market share captured by Consumables in 2023.

Based on Usage, the global Cell and Gene Therapy Biomanufacturing market has been segmented into Commercial Stage Manufacturing and Research Stage Manufacturing. Commercial Stage Manufacturing dominated the Cell and Gene Therapy Biomanufacturing Market as established therapies entered the commercialization phase. This phase requires significant manufacturing efforts to meet growing demand. With more therapies reaching this stage, the demand for manufacturing services surged, driving the market share of Commercial Stage Manufacturing Usage. Additionally, advancements in manufacturing technologies and processes further supported its dominance in 2023.

Based on application, the global Cell and Gene Therapy Biomanufacturing market has been segmented into Upstream Processing, Harvesting, and Downstream Processing. The Upstream Processing application claimed the largest market share in Cell and Gene Therapy Biomanufacturing due to its pivotal role in cell and gene therapy production. This phase involves cell culture expansion and modification, which is crucial for generating therapeutic cells. With the increasing demand for cell and gene therapies, the emphasis on optimizing upstream processes to enhance yield and quality propelled the dominance of Upstream Processing in 2023.

Based on End User, the global Cell and Gene Therapy Biomanufacturing market has been segmented into Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks. Life Science Companies emerged as the dominant End User in the Cell and Gene Therapy Biomanufacturing Market due to their expertise and infrastructure tailored for biomanufacturing processes. With a deep understanding of regulatory requirements and access to specialized equipment, these companies were well-positioned to lead in cell and gene therapy production. Their comprehensive capabilities and resources propelled them to capture the largest market share in 2023.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Cell Gene Therapy Biomanufacturing Market Research Report

Regional Analysis

The global Cell and Gene Therapy Biomanufacturing market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Cell and Gene Therapy Biomanufacturing market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Cell and Gene Therapy Biomanufacturing market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The rest of the world's cell and gene therapy biomanufacturing market comprises the Middle East, Africa, and Latin America.

North America has captured the largest market share in the Cell and Gene Therapy Biomanufacturing Market due to several factors. North America dominates the Cell and Gene Therapy Biomanufacturing Market due to several factors. The region boasts advanced infrastructure, a robust regulatory framework, and a strong presence of key industry players. Additionally, North America benefits from substantial investments in research and development, fostering innovation and technological advancements. Furthermore, favorable reimbursement policies and a high prevalence of chronic diseases contribute to the region's significant market share in cell and gene therapy biomanufacturing.

Europe has secured the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market due to several factors. Europe holds the second spot in the global cell and gene therapy market. Factors contributing to this position include increased investment in countries like the UK, strong support from regulatory bodies, and a well-established healthcare infrastructure. European companies are actively expanding their global reach, driving demand for these innovative therapies. Additionally, the region’s focus on research and development ensures long-term sustainability for companies operating in this market.

The Asia Pacific region is experiencing the highest compound annual growth rate (CAGR) in the Cell and Gene Therapy Biomanufacturing Market due to several factors. First, the region has witnessed an expansion in target indications for cell and gene therapies, driving demand for large-scale biomanufacturing facilities. Second, the entry of new market participants has further fueled this growth. Third, the robust clinical pipeline necessitates the development of novel therapies, leading to increased demand for biomanufacturing infrastructure. China, in particular, plays a significant role in driving the APAC market, which is projected to reach $2.71 billion by 2031 with a CAGR of 20.04%.

Furthermore, the rest of the world's Cell and Gene Therapy Biomanufacturing market is divided into the Middle East, Africa, and Latin America. The Rest of the World region is experiencing growth in the Cell and Gene Therapy Biomanufacturing market due to increasing investments in biotechnology, supportive regulatory frameworks, rising adoption of advanced manufacturing technologies, and expanding infrastructure for biomanufacturing activities, driving market expansion beyond traditional hubs.

Key Findings of the Study

• The global Cell and Gene Therapy Biomanufacturing market is expected to reach USD 31.2 billion by 2032, at a CAGR of 10.60% during the forecast period.


• The Asia Pacific region leads as the fastest-growing region in the Cell and Gene Therapy Biomanufacturing market due to its burgeoning biotechnology sector, supportive regulatory environment, substantial investment influx, and expanding manufacturing capabilities.


• Based on application, the upstream processing segment was attributed to holding the largest market in 2023.


• Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiv, and Novasep are the key market players.